First-in-Class Leukemia Drug Approved

Share this content:
FDA has approved Blincyto (blinatumomab; Amgen) for the treatment of B-cell ALL.
FDA has approved Blincyto (blinatumomab; Amgen) for the treatment of B-cell ALL.

The Food and Drug Administration (FDA) has approved Blincyto (blinatumomab; Amgen) for the treatment of patients with relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL).

Blincyto is a bispecific T-cell engager (BiTE) antibody construct, a first-in-class immunotherapy for this condition. It works by engaging the body's T-cells to destroy leukemia cells. It acts as a connector between CD19, which is found on most B-cell lymphoblast surfaces, and CD3, which is found on T-cell lymphocytes.

RELATED: Imatinib Most Common Kinase Inhibitor (TKI) for First-Line Treatment of Chronic Myeloid Leukemia

The safety and efficacy of Blincyto were studied in 185 adults with Philadelphia (-) relapsed or refractory B-cell ALL.After treatment with Blincyto for at least four weeks, 32% of patients showed complete remission for approximately 6.7 months.

Blincyto was granted breakthrough therapy designation, priority review, and orphan product designation. It is being approved under the FDA's accelerated approval pathway with a Risk Evaluation and Mitigation Strategy (REMS).

For more information call (800) 772-6436 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs